What question did this study set out to answer?

This review aims to evaluate the current landscape of CAR-T studies in systemic sclerosis, focusing on trial designs and outcomes.

Are We Putting the “Cart” Before the Horse in Systemic Sclerosis? A Review of the CAR-T Studies in Scleroderma

View Full Paper

Ask AI

Bookmark

Authors

Review identifies CAR-T therapy landscape in systemic sclerosis, suggesting improved trial designs for better outcomes.

This review aims to evaluate the current landscape of CAR-T studies in systemic sclerosis, focusing on trial designs and outcomes.
Reviewed 29 actively recruiting CAR-T trials for systemic sclerosis from ClinicalTrials.gov and ClinicalTrialsRegister.eu on August 20, 2026.
Extracted data including trial identifiers, comparative arms, eligibility criteria, and immunosuppression protocols.
Analyzed findings alongside recent case series to determine feasibility and clinical benefits.
27 out of 29 trials targeted CD19, with few trials showing clinical benefit in early diffuse cutaneous systemic sclerosis.
Only 2 randomized trials; one included rituximab as a comparator, indicating limited comparative designs.
Reports noted deep B-cell depletion and improved skin and lung disease, although safety concerns were low-grade.

Toro-Gutierrez et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark